The US Food and Drug Administration (USFDA) has added one more clause in its import alert given to the drug maker, Divi's Laboratories Limited. The USFDA is alleging the Company of ‘refusal for inspection’. Divi's Laboratories has been reeling under pressure due to USFDA’s import alert.

However, the Company has not yet disclosed the details of the new clause added by the US health regulator. The US health regulator has recently banned a drug production facility of the Company, in India. The actions taken by USFDA may make an impression that the Company’s products are manufactured, processed or packed in an unhygienic manner.

Divi's stock is trading under pressure for past few trading sessions. The stock had touched its fresh 52 week low of Rs 611.45 per share in Wednesday’s trading session.